GPE vs PACAP-38
Head-to-head comparison of GPE (Glycyl-L-prolyl-L-glutamic acid) and PACAP-38 (Pituitary Adenylate Cyclase-Activating Polypeptide-38 (human PACAP-38)) — benefits, dosing, side effects, research data, and where to buy.
| Property | GPE | PACAP-38 |
|---|---|---|
| Category | Cognitive Enhancement | Cognitive Enhancement |
| Full Name | Glycyl-L-prolyl-L-glutamic acid | Pituitary Adenylate Cyclase-Activating Polypeptide-38 (human PACAP-38) |
| Molecular Weight | 301.30 Da | 4534 Da |
| Half-Life | minutes | minutes |
| Amino Acids | 3 | 38 aa |
| Typical Dose | 0.1-10 mg/kg preclinical | 10-100 µg preclinical range |
| Route | Intranasal/Intracerebroventricular | Intranasal |
| Purity | ≥98% | ≥98% |
| Studies Count | 25 | 650 |
| Research Status | Pre-clinical | Pre-clinical |
GPE Benefits
- ✓memory consolidation
- ✓neuroprotection
- ✓synaptic plasticity
- ✓learning support
PACAP-38 Benefits
- ✓synaptic plasticity
- ✓BDNF upregulation
- ✓neuroprotection
- ✓memory consolidation
GPE Dosing
intranasal or ICV research doses|0.1-10 mg/kg preclinical range|repeat daily or intermittent protocols
PACAP-38 Dosing
0.1-1 nmol ICV in rodents|10-100 µg intranasal in preclinical studies|single-dose or short repeated protocols
GPE Side Effects
- ⚠limited human safety data
- ⚠short half-life
- ⚠local irritation with nasal delivery
PACAP-38 Side Effects
- ⚠headache-like effects
- ⚠flushing
- ⚠hypotension
Research Overview
GPE
Preclinical studies suggest GPE can reduce neuronal damage and support plasticity-related pathways in the brain. Research interest centers on hippocampal function, which links it to learning and memory paradigms.
PACAP-38
PACAP-38 is one of the most studied endogenous neuropeptides for protecting neurons from ischemic and excitotoxic damage. Preclinical literature also links it to hippocampal plasticity and learning-related signaling, including increased BDNF expression.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.